Careers  |  Sign In  |  Register

FDA Meets to Discuss Ethics of “Three-Parent IVF” Therapy

The Washington Post reports that an FDA panel sat down on Tuesday for a two-day meeting discussing the ethics of a new “three-parent IVF” therapy. The therapy replaces mutated mitochondria in the mother’s egg and replacing them with healthy mitochondria from a donor to prevent the passing on genetic mutations. The egg can then be fertilized by the father’s sperm in the lab. Experts and ethicists worry that “the technology raises grave safety concerns and could open the door to creating ‘designer’ babies, whose eye color, intelligence and other characteristics are selected by parents.” An approval of the technique would mark the first time the FDA approved a gene-modification technique “whose effect if transmitted to a person’s descendants.”

Read the article published in The Washington Post.